GSK plc announced that the European Medicines Agency has validated the company’s Type II Variation for a potential new indication for Jemperli in combination with chemotherapy for the treatment of adult patients with a type of gynaecological cancer known as mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer. As a result, the EMA’s Committee for Medicinal Products for Human Use will begin the formal review process to make a recommendation to the European Commission regarding marketing authorization for the potential new indication.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK:
- Bellus Health cut to Sector Perform at RBC Capital on GSK deal
- GSK to acquire Bellus Health for $14.75 per share
- Bellus Health Surges after Acquisition by GSK for $2 Billion
- GSK reports EAGLE-2 and EAGLE-3 phase III trials met primary endpoint
- Return of Adaptimmune assets complements TCR pipeline, says Guggenheim